Serum Prostaglandin D Synthase Level after Coronary Angioplasty May Predict Occurrence of Restenosis

Summary

Lipocalin-type prostaglandin D synthase (L-PGDS), which is responsible for the biosynthesis of PGD₂, has recently been found to be present in the atherosclerotic plaque of the human coronary artery and also to be secreted in human serum. We measured the serum L-PGDS level and compared it with the expressions of the platelet membrane surface glycoprotein and neutrophil adhesion molecule in patients undergoing PTCA. The L-PGDS level significantly decreased (P < 0.01) and the platelet surface expression of CD62P (P-selectin) significantly increased (P < 0.01) immediately after PTCA in the coronary sinus blood. Both changes were inversely correlated (R = −0.72, P < 0.001). Although the L-PGDS level in the coronary sinus blood remained equivalent to the baseline level in patients who experienced restenosis, the level increased over the baseline level (P < 0.01) at 48 h after PTCA in patients without restenosis. Neutrophil surface expression of CD11b (a subunit of Mac-1) significantly increased at 24 h (P < 0.01) to 48 h (P < 0.001) after PTCA in the coronary sinus blood in patients with restenosis but the change showed less significant in patients without restenosis. The changes in the L-PGDS level and the CD11b expression at 48 h after PTCA were inversely correlated (R = −0.55, P < 0.05). An increased serum L-PGDS level at 48 h after PTCA possibly predicts the avoidance of late restenosis. It is suggested that reduction in PGD₂ synthesis triggers platelet activation and that a subsequent increase in the PGD₂ synthesis suppresses inflammatory reaction at the intervention site indicated by neutrophil activation and inhibits development of restenosis. Pharmacological or biological intervention that increases endogenous PGD₂ synthesis should be tested as a new strategy to prevent restenosis.

Keywords

Prostaglandin D synthase - prostaglandin D₂ - platelet - neutrophil - restenosis

• References

• 1 Ito S, Narumiya S, Hayaishi O. Prostaglandin D₂: a biochemical perspective. Prostaglandins Leukot Essent Fatty Acids 1989; 37: 219-34.
• 2 Urade Y, Watanabe K, Hayaishi O. Prostaglandin D, E, and F syntases. J Lipid Mediator Cell Signalling 1995; 12: 257-73.
• 3 Urade Y, Hayaishi O. Prostaglandin D₂ and sleep regulation. Biochim Biophys Acta 1999; 1436: 606-15.
• 4 Eguchi N, Minami T, Shirafuji N, Kanaoka Y, Tanaka T, Nagata A, Yoshida N, Urade Y, Ito S, Hayaishi O. Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. Proc Natl Acad Sci USA 1999; 96: 726-30.
• 5 Bushfield M, McNicol A, MacIntyre DE. Inhibition of platelet-activating-factor-induced human platelet activation by prostaglandin D₂: differential sensitivity of platelet transduction processes and functional response to inhibition by cyclic AMP. Biochem J 1985; 232: 267-71.
• 6 Negishi M, Sugimoto Y, Ichikawa A. Prostanoid receptors and their biological actions. Prog Lipid Res 1993; 32: 417-34.
• 7 Urade Y, Fujimoto N, Hayaishi O. Purification and characterization of rat brain prostaglandin D synthase. J Biol Chem 1985; 260: 12410-5.
• 8 Hoffman A, Conradt HS, Gross G, Nimtz M, Lottspeich F, Wurster U. Purification and chemical characterization of β-trace protein from human cerebrospinal fluid: its identification as prostaglandin D synthase. J Neurochem 1993; 61: 451-6.
• 9 Watanabe K, Urade Y, Mäder M, Murphy C, Hayaishi O. Identification of β-trace as prostaglandin D synthase. Biochem Biophys Res Commun 1994; 203: 1110-6.
• 10 Eguchi Y, Eguchi N, Oda H, Seiki K, Kijima Y, Matsu-ura Y, Urade Y, Hayaishi O. Expression of lipocalin-type prostaglandin D synthase (β-trace) in human heart and its accumulation in the coronary circulation of angina patients. Proc Natl Acad Sci USA 1997; 94: 14689-94.
• 11 Oda H, Eguchi N, Urade Y, Hayaishi O. Quantitative sandwich enzyme-linked immunosorbent assay for human secretory prostagrandin D synthase (β-trace). Proc Japan Acad 1996; 72: 108-11.
• 12 Lie MW, Roubin GS, King III SB. Restenosis after coronary angioplasty: potential biologic determinants and roles of intimal hyperplasia. Circulation 1989; 79: 1374-87.
• 13 Karas SP, Santoian EC, Gravanis MB. Restenosis following coronary angioplasty. Clin Cardiol 1991; 14: 791-801.
• 14 Ricevuti G, Mazzone A, Pasotti D, De Servi S, Specchia G. Role of granulocytes in endothelial injury in coronary heart disease in humans. Atherosclerosis 1991; 91: 1-14.
• 15 Newmann FJ, Ott I, Gawaz M, Puchner G, Schömic A. Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. J Am Coll Cardiol 1996; 27: 819-24.
• 16 Bruhring HJ, Asenbauer B, Katrilaka K, Humel G, Busch FW. Sequential expression of CD34 and CD33 antigens on myeloid colony-forming cells. Eur J Haematol 1989; 42: 143-9.
• 17 Wells DA, Daigneault-Creech CA, Simrell CR. Effect of iron status on reticulocyte mean channel fluorescence. Am J Clin Pathol 1992; 97: 130-4.
• 18 Stephen HI, Ritterhaus CW, Hearley KW, Struzziero CC, Hoffman RA, Hansen PW. Rapid enumeration of T lymphocytes by a flow-cytometric immunofluorescence method. Clin Chem 1982; 28: 1905-9.
• 19 Uehara Y, Tobian L, Iwai J, Ishii M, Sugimoto T. Alteration of vascular prostacyclin and thromboxane A2 in Dahl genetical strain susceptible to salt-induced hypertension. Prostaglandins 1987; 33: 727-38.
• 20 Inoue T, Hoshi K, Fujito T, Sakai Y, Morooka S, Sohma R. Early detection of platelet activation after coronary angioplasty. Coron Artery Dis 1996; 7: 529-34.
• 21 Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991; 17: 758-69.
• 22 Liw MW, Roubin GS, King III SB. Restenosis after coronary angioplasty: potential biologic determinants and role of intimal hyperplasia. Circulation 1989; 79: 1374-87.
• 23 Nagoshi H, Uehara Y, Kanai F, Maeda S, Ogura T, Goto A, Toyo-oka T, Esumi H, Shimizu T, Omata M. Prostaglandin D₂ inhibits inducible nitric oxide synthase expression in rat vascular smooth muscle cells. Circ Res 1998; 82: 204-9.
• 24 Sobey CG, Brooks RM, Heistad DD. Evidence that expression of inducible nitric oxide synthase in response to endotoxin is augumented in atherosclerotic rabbits. Circ Res 1995; 77: 536-54.
• 25 Minor RL, Myers PR, Guerra R, Bates JN, Harrison DG. Diet-induced atherosclerosis increases the release of nitrogen oxide from rabbit aorta. J Clin Invest 1990; 86: 2119-26.
• 26 Freuyer DR, Morganroth ML, Todd RF. 1989; Surface Mo1 (CD11b/CD18) glycoprotein is up-modulated by neutrophils recruited to sites of inflammation in vivo. Inflammation 13: 495-505.
• 27 Inoue T, Sakai Y, Morooka S, Hayashi T, Takayanagi K, Takabatake Y. Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1996; 28: 1127-33.
• 28 Inoue T, Sakai Y, Fujito T, Hoshi K, Hayashi T, Takayanagi K, Morooka S. Clinical significance of neutrophil adhesion molecules expression after coronary angioplasty on the development of restenosis. Thromb Haemost 1998; 79: 54-8.
• 29 Inoue T, Sakai Y, Hoshi K, Yaguchi I, Fujito T, Morooka S. Lower expression of neutrophil adhesion molecule indicates less vessel wall injury and might explain lower restenosis rate after Cutting Balloon angioplasty. Circulation 1998; 97: 2511-8.